Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Claudin-18.2

Claudin-18.2

Brief Information

Name:Claudin-18 splice variant 2
Target Synonym:UNQ778/PRO1572,CLDN18,Claudin 18,Surfactant Associated Protein J,Surfactant, Pulmonary Associated Protein J,Surfactant Associated 5,Claudin-18,SFTA5,SFTPJ,Claudin 18.2,CLDN18.2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:61
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CLDN18.2 CAR-T - 01 PhaseI Solid Tumor Advanced refractory gastrointestinal tumors
CLDN18.2 VHH - 01 Lead Solid Tumor Gastric Cancer,Pancreatic cancer

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
Claudin18.2 mAb Monospecific antibody Oncology/Cancer Gastric cancer Phase I Global
Claudin18.2×CD8+ T bsAb Bispecific antibody Oncology/Cancer Gastric cancer,Pancreatic cancer,Oophoroma IND Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CL2-HF218-Cell-based assay
 Claudin-18.2 FACS

2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).

CHEK-ATP033-Cell-based assay
 Claudin-18.2 FACS

FACS assay shows that Anti-Claudin-18.2 antibody can bind to HEK293/Human Claudin-18.2 Stable Cell Line. HEK293/Human Claudin-18.2 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).

CL2-H5586-SPR
 Claudin-18.2 SPR

Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 captured on Protein A Chip can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5586) with an affinity constant of 12.6 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

CL2-M5585-SPR
 Claudin-18.2 SPR

Claudin-18.1 Monoclonal Antibody captured on CM5 chip via anti-mouse antibodies surface can bind Mouse Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-M5585) with an affinity constant of 13 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

Synonym Name

Claudin-18.2,CLDN18,Claudin-18

Background

Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BA-1105 BA-1105 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
PM-3023 PM-3023 Phase 1 Clinical Biotheus Inc Solid tumours Details
QL-1779 QL-1779; QL1779 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours Details
JS-012 JS-012 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
RD-07 RD-07 Phase 1 Clinical Peking University Solid tumours Details
Gresonitamab AMG-910 Phase 1 Clinical Amgen Inc Stomach Neoplasms Details
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) AB-011 Phase 1 Clinical Kaixing Life Technology (Shanghai) Co Ltd Solid tumours Details
DR-30303 DR30303 Phase 1 Clinical Zhejiang Doer Biologics Corp Solid tumours Details
KD-182 KD-182 Phase 2 Clinical Nanjing Kaedi Biotechnology Co Ltd Stomach Neoplasms; Carcinoma, Pancreatic Ductal Details
BNT-141 BNT-141 Phase 2 Clinical Biontech Se Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Esophageal adenocarcinoma; Neoplasm Metastasis; Adenocarcinoma Details
M-108 M108; M-108 Phase 1 Clinical FutureGen Biopharm (Beijing) Co Ltd Solid tumours Details
124I-18B10 124-I-18-B-10; 124I-18B10 Clinical Transcenta Holding Ltd, Beijing Cancer Hospital Gastrointestinal Neoplasms Details
LY-011(Shanghai Longyao) LY-011 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Stomach Neoplasms; Pancreatic Neoplasms Details
LB-1904 LB-1904 Phase 1 Clinical Stomach Neoplasms Details
CT-048 CT-048; KJ-C1807; KJ-C-1807 Phase 1 Clinical Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
NBL-015 NBL-015 Phase 1 Clinical Shanghai Xinshi Biological Medicine Co Ltd Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms Details
HEC-016 HEC-016 Phase 1 Clinical People Hospital Of Luohu,Shenzhen Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
IM-92 IM-92 Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
IBI-345 IBI-345 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
SOT-102 SOT102; SO-N102; SOT-102 Phase 2 Clinical Sotio Biotech AG Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms Details
Zolbetuximab iMAB-362; GC-182 Phase 3 Clinical Ganymed Lymphangioma, Cystic; Solid tumours; Pain; Stomach Neoplasms; Esophageal Neoplasms; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma Details
Q-1802 Q-1802 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Gastrointestinal Neoplasms Details
Recombinant humanized monoclonal antibody MIL93(Mabworks) MIL-93 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Neoplasms Details
QLS-31905 QLS-31905 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
IBI-360 IBI-360 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
IBI-389 IBI-389 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
JS-107 JS-107 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
CMG-901(Connaught Biomedical Technology) CMG-901 Phase 1 Clinical Keymed Biosciences Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
IMC-002(Suzhou Immunofoco) IMC-002 Phase 1 Clinical Suzhou Immunofoco Biotechnology Co Ltd Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
LM-302 LM-302; TPX-4589 Phase 2 Clinical Eli Lilly Trading (Shanghai) Co Ltd Solid tumours Details
CLDN18.2 UCAR-T cell therapy CLDN18.2 UCAR-T Clinical Zhongshan City People'S Hospital, Suzhou Maoxing Biotechnology Co Ltd Stomach Neoplasms Details
SKB-315 SKB-315; SKB315 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours; Neoplasms Details
KD-496 KD-496(4th); KD-496 Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms Details
CT-041 CT041 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
LM-102 LM-102 Phase 2 Clinical LaNova Medicines Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms Details
SG-1906 SG-1906; SG1906 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Neoplasms Details
BC-007 (Dragonboat Biopharmaceutical) BC-007 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
SHR-A-1904 SHR-A-1904; SHR-A1904 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Pancreatic Neoplasms; Neoplasms Details
PM-1032 PM1032; PM-1032 Phase 1 Clinical Biotheus Inc, Shanghai Genechem Co Ltd Neoplasms Details
Osemitamab MSB-018; TST-001 Phase 2 Clinical Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Lung Neoplasms; Gallbladder Neoplasms Details
LB-4330 Bis-2; LB-4330 Phase 1 Clinical L&L Biopharma Co Ltd Solid tumours Details
IBI-343 IBI-343 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
BC-008 BC-008 Phase 1 Clinical Dragonboat Biopharmaceutical Solid tumours; Neoplasms Details
ASP-2138 ASP-2138 Phase 1 Clinical Astellas Pharma Global Development Inc, Xencor Inc Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
SPX-101 (Sparx Therapeutics) SX-001; KY-71113; KY71113; SPX-101 Phase 1 Clinical Kpc Pharmaceuticals Inc Solid tumours; Stomach Neoplasms Details
RC-118 RC-118; YH005 ADC Phase 2 Clinical RemeGen Co Ltd, Beijing Biocytogen Co Ltd Solid tumours; Neoplasm Metastasis Details
LCAR-C18S CAR-T cell therapy LB-1908; LCAR-C18S; LCAR-C-18-S Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
ZL-1211 ZL-1211 Phase 2 Clinical Zai Lab (Shanghai) Co Ltd Solid tumours Details
ASKB-589 ASKB-589 Phase 2 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Adenocarcinoma Details
PT-886 PT-886 Phase 1 Clinical Phanes Therapeutics Inc Stomach Neoplasms; Pancreatic Neoplasms Details
SYSA-1801 SYSA-1801; SYSA1801; CPO-102; EO-3021 Phase 1 Clinical Jushi Biopharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms Details
TJ-CD4B TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-CD4B/ABL111; TJ-033721 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message